Skip to main content
SpringerLink
Log in

Axonal degeneration and progressive neurologic disability in multiple sclerosis

  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Accumulating data support axonal degeneration as the major determinant of irreversible neurological disability in patients with multiple sclerosis (MS). The extent of oxonal injury correlates with the degree of inflammation in active MS lesions and occurs at early stages of disease, indicating that inflammatory demyelination is an important factor behind axon pathology at the relapsing-remitting stage of MS. Axonal loss from disease onset can remain clinically silent for many years, and permanent neurological disability develops when a threshold of axonal loss is reached and the CNS compensatory resources are exhausted. Lack of myelinderived trophic support due to long term demyelination may cause continous axonal degeneration in chronic inactive lesions at the secondary-progressive stage of MS. Axonal pathology is not limited to demyelinated lesions, but also extends into normal appearing white matter. The concept of MS as a neurodegenerative disorder has important clinical implications: First, proactive anti-inflammatory and immunomodulatory treatment should prevent or delay chronic disability since inflammation influences axonal injury. Second, the pathophysiological mechanisms underlying axonal degeneration in MS need to be clarified in order to develop novel neuroprotective therapeutics. Finally, surrogate markers of axonal pathology, such asN-acetyl aspartate, can be used to monitor axonal axonal dysfunction, axonal loss and treatment efficiency in patients with MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anzini P, DH Neuberg, M Schachner, E Nelles, K Willecke, J Zielasek, KV Toyka, U Suter and R Martini (1997) Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32.J. Neurosci. 17, 4545–4551.

    PubMed  CAS  Google Scholar 

  • Arnold DL, GT Reiss, PM Matthews, GS Francis, DL Collins, C Wolfson and JP Antel (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.Ann. Neurol. 36, 76–82.

    Article  PubMed  CAS  Google Scholar 

  • Barnes D, PMG Munro, BD Youl, JW Prineas and WI McDonald (1991) The longstanding MS lesion.Brain 114, 1271–1280.

    Article  PubMed  Google Scholar 

  • Bjartmar C and BD Trapp (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences.Curr. Opin. Neurol. 14, 271–278.

    Article  PubMed  CAS  Google Scholar 

  • Bjartmar C, X Yin and BD Trapp (1999) Axonal pathology in myelin disorders.J. Neurocytol. 28, 383–395.

    Article  PubMed  CAS  Google Scholar 

  • Bjartmar C, G Kidd, S Mörk, R Rudick and BD Trapp (2000) Neurological disability correlates with spinal cord axonal loss and reducedN-acetyl aspartate in chronic multiple sclerosis patients.Ann. Neurol. 48, 893–901.

    Article  PubMed  CAS  Google Scholar 

  • Bjartmar C, RP Kinkel, G Kidd, RA Rudick and BD Trapp (2001a) Axonal loss in normal-appearing white matter in a patient with acute MS.Neurology 57, 1248–1252.

    PubMed  CAS  Google Scholar 

  • Bjartmar C, J Battistuta, N Terada, E Dupree and BD Trapp (2001b)N-acetyl aspartate is an axon specific marker of mature white matterin vivo: a biochemical and immunohistochemical study on the rat optic nerve.Ann. Neurol. 51, 51–58.

    Article  Google Scholar 

  • Bjartmar C, G Kidd and Ransohoff (2001c) A real-time insight into disease progression and the role of axonal injury in multiple sclerosis.Arch. Neurol. 58, 37–39.

    Article  PubMed  CAS  Google Scholar 

  • Charcot M (1868) Histologie de le sclerose en plaques.Gazette Hopitaux 141, 554–558.

    Google Scholar 

  • Clark JB (1998)N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction.Dev. Neurosci. 20, 271–276.

    Article  PubMed  CAS  Google Scholar 

  • Confavreux C, S Vukusic, T Moreau and P Adeleine (2000) Relapses and progression of disability in multiple sclerosis.N. Engl. J. Med. 343, 1430–1438.

    Article  PubMed  CAS  Google Scholar 

  • Davie CA, GJ Barker, S Webb, PS Tofts, AJ Thompson, AE Harding, WI McDonald and DH Miller (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.Brain 118, 1583–1592.

    Article  PubMed  Google Scholar 

  • De Stefano N, PM Matthews and DL Arnold (1995) Reversible decreases inN-acetylaspartate after acute brain injury.Magn. Reson. Med. 34, 721–727.

    Article  PubMed  Google Scholar 

  • De Stefano N, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, JP Antel and DL Arnold (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.Brain 121, 1469–1477.

    Article  PubMed  Google Scholar 

  • Evangelou N, MM Esiri, S Smith, J Palace and PM Matthews (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.Ann. Neurol. 47, 391–395.

    Article  PubMed  CAS  Google Scholar 

  • Ferguson B, MK Matyszak, MM Esiri and VH Perry (1997) Axonal damage in acute multiple sclerosis lesions.Brain 120 393–399.

    Article  PubMed  Google Scholar 

  • Filippi M, B Colombo, M Rovaris, C Pereira, V Martinelli and G Comi (1997) A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis.J. Neuroimaging 7, 78–80.

    PubMed  CAS  Google Scholar 

  • Fu L, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, JP Antel, C Wolfson and DL Arnold (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis.Brain 121, 103–113.

    Article  PubMed  Google Scholar 

  • Ganter P, C Prince and MM Esiri (1999) Spinal cord axonal loss in multiple sclerosis: a post-mortem study.Neuropathol. Appl. Neurobiol. 25, 459–467.

    Article  PubMed  CAS  Google Scholar 

  • Giese KP, R Martini, G Lemke, P Soriano and M Schachner (1992) Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons.Cell 71, 565–576.

    Article  PubMed  CAS  Google Scholar 

  • Gonen O, I Catalaa, JS Babb, Y Ge, LJ Mannon, DL Kolson and RI Grossman (2000) Total brainN-acetylaspartate. A new measure of disease load in MS.Neurology 54, 15–19.

    PubMed  CAS  Google Scholar 

  • Graham GD, AM Blamire, AM Howseman, DL Rothman, PB Fayad, LM Brass, OA Petroff, RG Shulman and JW Prichard (1992) Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients.Stroke 23, 333–340.

    PubMed  CAS  Google Scholar 

  • Griffiths I, M Klugmann, T Anderson, D Yool, C Thomson, MH Schwab, A Schneider, F Zimmermann, M McCulloch, N Nadon and K-A Nave (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin.Science 280, 1610–1613.

    Article  PubMed  CAS  Google Scholar 

  • Holfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.Brain 120, 865–916.

    Article  Google Scholar 

  • Kidd D, JW Thorpe, AJ Thompson, BE Kendall, IF Mosley, DG MacManus, WI McDonald and DH Miller (1993) Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis.Neurology 43, 2632–2637.

    PubMed  CAS  Google Scholar 

  • Kidd D, F Barkhof, R McConnell, PR Algra, IV Allen and T Revesz (1999) Cortical lesions in multiple sclerosis.Brain 122, 17–26.

    Article  PubMed  Google Scholar 

  • Koo EH, SS Sisodia, DR Archer, LJ Martin, A Weidemann, K Beyreuther, P Fischer, CL Masters and DL Price (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.Proc. Natl. Acad. Sci. USA 87, 1561–1565.

    Article  PubMed  CAS  Google Scholar 

  • Kornek B and H Lassman (1999) Axonal pathology in multiple sclerosis. A historical note.Brain Pathol. 9, 651–656.

    PubMed  CAS  Google Scholar 

  • Lee MA, AM Blamire, S Pendlebury, KH Ho, KR Mills, P Styles, J Palace and PM Matthews (2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis.Arch. Neurol. 57, 65–70.

    Article  PubMed  CAS  Google Scholar 

  • Losseff NA, SL Webb, JI O'Riordan, R Page, L Wang, GJ Barker, PS Tofts, WI McDonald, DH Miller and AJ Thompson (1996a) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.Brain 119, 701–708.

    Article  PubMed  Google Scholar 

  • Losseff NA, L Wang, HM Lai, DS Yoo, ML Gawne-Cain, WI McDonald, DH Miller and AJ Thompson (1996b) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.Brain 119, 2009–2019.

    Article  PubMed  Google Scholar 

  • Lovas G, N Szilagyi, K Majtenyi, M Palkovits and S Komoly (2000) Axonal changes in chronic demyelinated cervical spinal cord plaques.Brain 123, 308–317.

    Article  PubMed  Google Scholar 

  • Matthews PM, E Pioro, S Narayanan, N De Stefano, L Fu, G Francis, J Antel, C Wolfson and DL Arnold (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy.Brain 119, 715–722.

    Article  PubMed  Google Scholar 

  • Matthews PM, N De Stefano, S Narayanan, GS Francis, JS Wolinsky, JP Antel and DL Arnold (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis.Semin. Neurol. 18, 327–336.

    Article  PubMed  CAS  Google Scholar 

  • McFarland HF, JA Frank, PS Albert, ME Smith, R Martin, JO Harris, N Patronas, H Maloni and DE McFarlin (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.Ann. Neurol. 32, 758–766.

    Article  PubMed  CAS  Google Scholar 

  • Mews I, M Bergmann, S Bunkowski, F Gullotta and W Brück (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions.Multiple Sclerosis,4, 55–62.

    PubMed  CAS  Google Scholar 

  • Moffett JR, MAA Namboodiri, CB Cangro and JH Neale (1991) Immunohistochemical localization ofN-acetylaspartate in rat brain.Neuroreport 2, 131–134.

    Article  PubMed  CAS  Google Scholar 

  • Narayanan S, L Fu, E Pioro, N De Stefano, DL Collins, G Francis, JP Antel, PM Matthews and DL Arnold (1997) Imaging of axonal damage in multiple sclerosis: spatial distribution, of magnetic resonance imaging lesions.Ann. Neurol. 41, 385–391.

    Article  PubMed  CAS  Google Scholar 

  • Narayana PA, TJ Doyle, L Dejian and JS Wolinsky (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.Ann. Neurol. 43, 56–71.

    Article  PubMed  CAS  Google Scholar 

  • Noseworthy JH, C Luccinetti, M Rodriquez and BG Weinshenker (2000) Multiple sclerosis.N. Engl. J. Med. 343, 938–952.

    Article  PubMed  CAS  Google Scholar 

  • Patel TB and JB Clark (1979) Synthesis ofN-acetyl-L-aspartate by rat brain mitochondria and involvement in mitochondrial/cytosolic carbon transport.Biochem. J. 184, 539–546.

    PubMed  CAS  Google Scholar 

  • Peterson JW, L Bö, S Mörk, A Chang and BD Trapp (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann. Neurol. 50, 389–400.

    Article  PubMed  CAS  Google Scholar 

  • Pioro E, JP Antel, NR Cashman and DL Arnold (1994) Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imagingin vivo.Neurology 44, 1933–1938.

    PubMed  CAS  Google Scholar 

  • Pitt D, P Werner and CS Raine (2000) Glutamate excitotoxicity in a model of multiple sclerosis.Nature Med. 6, 67–70.

    Article  PubMed  CAS  Google Scholar 

  • Reddy H, S Narayanan, R Arnoutelis, M Jenkinson, J Antel, PM Matthews and DL Arnold (2000) Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis.Brain 123, 2314–2320.

    Article  PubMed  Google Scholar 

  • Rudick RA, JA Cohen, B Weinstock-Guttman, RP Kinkel and RM Ransohoff (1997) Management of multiple sclerosis.N. Engl. J. Med. 337, 1604–1611.

    Article  PubMed  CAS  Google Scholar 

  • Rudick RA, E Fisher, JC Lee, J Simon and L Jacobs (1999a) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.Neurology 53, 1698–1704.

    PubMed  CAS  Google Scholar 

  • Rudick RA, A Goodman, RM Herndon and HS Panitch (1999b) Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment.J. Neuroimmunol. 98, 22–28.

    Article  PubMed  CAS  Google Scholar 

  • Sahenk Z, L Chen and JR Mendell (1999) Effects of PMP22 duplication and deletions on the axonal cytoskeleton.Ann. Neurol. 45, 16–24.

    Article  PubMed  CAS  Google Scholar 

  • Scherer S (1999) Axonal pathology in demyelinating diseases.Ann. Neurol. 45, 6–7.

    Article  PubMed  CAS  Google Scholar 

  • Simmons ML, CG Frondoza and JT Coyle (1991) Immunocytochemical localization ofN-acetyl-aspartate with monoclonal antibodies.Neuroscience 45, 37–45.

    Article  PubMed  CAS  Google Scholar 

  • Simon JH, LD Jacobs, MK Campion, RA Rudick, DL Cookfair, RM Herndon, JR Richert, AM Salazar, JS Fisher, DE Goodkin, N Simonian, M Lajaunie, DE Miller, K Wende, A Martens-Davidson, RP Kinkel, FE Munschauer, CM Brownscheidle and The Multiple Sclerosis Collaborative Research Group (MSCRG) (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis.Neurology 53, 139–148.

    PubMed  CAS  Google Scholar 

  • Simon, JH, RP Kinkel, L Jacobs, L Bub and N Simonian (2000) A Wallerian degeneration pattern in patients at risk for MS.Neurology 54, 1155–1160.

    PubMed  CAS  Google Scholar 

  • Stevenson VL and DH Miller (1999) Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis.Multiple Sclerosis 5, 268–272.

    PubMed  CAS  Google Scholar 

  • Trapp BD, J Peterson, RM Ransohoff, R Rudick, S Mörk and L Bö (1998) Axonal transection in the lesions of multiple sclerosis.N. Engl. J. Med. 338, 278–285.

    Article  PubMed  CAS  Google Scholar 

  • Trapp BD, RM Ransohoff, E Fisher and RA Rudick (1999) Neurodegeneration in multiple sclerosis: relationship to neurological disability.Neuroscientist 5, 48–57.

    Article  Google Scholar 

  • Truckenmiller ME, MAA Namboodiri, MJ Brownstein and JH Neale (1985)N-acetylation of L-aspartate in the nervous system: Differential distribution of a specific enzyme.J. Neurochem. 45, 1658–1662.

    Article  PubMed  CAS  Google Scholar 

  • de Waegh SM, VM-Y Lee and ST Brady (1992) Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells.Cell 68, 451–463.

    Article  PubMed  Google Scholar 

  • van Waesberghe JHTM, W Kamphorst, CJA De Groot, MAA van Walderveen, JA Castelijns, R Ravid, GJ Lycklama a Nijeholt, P van der Valk, CH Polman, AJ Thompson and F Barkhof (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.Ann. Neurol. 46, 747–754.

    Article  PubMed  Google Scholar 

  • Waxman SG (1998) Demyelinating diseases — new pathological insights, new therapeutic targets.N. Engl. J. Med. 338, 223–225.

    Article  Google Scholar 

  • Yin X, TO Crawford, JW Griffin, P Tu, VM-Y Lee, C Li, J Roder and BD Trapp (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons.J. Neurosci. 18, 1953–1962.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., 44195, Cleveland, OH, USA

    Carl Bjartmar & Bruce D. Trapp

Authors
  1. Carl Bjartmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce D. Trapp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce D. Trapp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bjartmar, C., Trapp, B.D. Axonal degeneration and progressive neurologic disability in multiple sclerosis. neurotox res 5, 157–164 (2003). https://doi.org/10.1007/BF03033380

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03033380

Keywords

Search

Navigation